XERIJECT
Live / Registered — Registered (as of 17 Oct 2023)
What this means for you
Registered since 17 Oct 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90980394
- Registration number
- 7197021
- Mark type
- Stylized text
- Filed
- 04 Dec 2020
- Published for opposition
- 29 Jun 2021
- Registered
- 17 Oct 2023
- Attorney of record
- Tracy-Gene G. Durkin
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical research and development; pharmaceutical drug formulation and development services; providing information on drug technology platforms for the formulation and development of drugs and biologics
Owner
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
Prosecution history
- 17 Oct 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Oct 2023 — REGISTERED-PRINCIPAL REGISTER
- 14 Sept 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 13 Sept 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 12 Sept 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 24 Aug 2023 — USE AMENDMENT FILED
- 12 Sept 2023 — DIVISIONAL PROCESSING COMPLETE
- 24 Aug 2023 — DIVISIONAL REQUEST RECEIVED
- 30 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 Aug 2023 — TEAS REQUEST TO DIVIDE RECEIVED
- 24 Aug 2023 — TEAS STATEMENT OF USE RECEIVED
- 02 Feb 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Jan 2023 — SOU EXTENSION 3 GRANTED
- 31 Jan 2023 — SOU EXTENSION 3 FILED
- 31 Jan 2023 — SOU TEAS EXTENSION RECEIVED